The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 18 of the 49 sources its claims cite were checked for support.
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Open accessAbstract
Obesity and type 2 diabetes mellitus (T2DM) are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy. This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile. Retatrutide's unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes. Animal studies demonstrate retatrutide's ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies. Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease. Common adverse effects are primarily gastrointestinal and dose-related. Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide's long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BMI reduction warrant further investigation. Retatrutide heralds a new era in obesity and T2DM treatment, offering hope for improved patient outcomes.
Overview
CoChat Summary
TL;DR
This is a narrative review of retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, arguing that it is a promising new option for obesity and T2DM. The paper reports strong phase I/II signals for weight loss, HbA1c reduction, and liver-fat improvement, but emphasizes that phase III data, cost issues, and body-composition outcomes are still needed.
Key findings
- In a phase 1 study, 47 healthy individuals entered and 45 received at least one dose; retatrutide reached maximum concentration in 12–72 h, had a mean half-life of about 6 days, and reduced body weight at all dose levels except 0.1 mg.
- In a 48-week phase II obesity trial, 338 adults were enrolled; least-squares mean body-weight change at 24 weeks ranged from −7.2% (1 mg) to −17.5% (12 mg) versus −1.6% with placebo, and at 48 weeks from −8.7% (1 mg) to −24.2% (12 mg) versus −2.1% with placebo.
- In a phase II diabetes trial, HbA1c at 24 weeks fell by up to −2.02% in the 12 mg escalation group versus −0.01% with placebo; body weight at 36 weeks decreased by up to 16.94% in the 12 mg escalation group.
- In a liver-fat substudy, 98 patients with ≥10% liver fat were randomized; mean relative liver-fat change at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg), versus +0.3% with placebo, and 76 participants completed the substudy.
Methods
- Narrative literature review using Medline with the keywords retatrutide, T2DM, obesity, and novel pharmacotherapy, combined with AND/OR.
- Included English-language articles published from 2005 onward; the most recent search was in April 2025.
- The paper synthesizes preclinical and clinical studies, including phase I and II trials and animal experiments, to describe mechanism, efficacy, and safety.
Limitations
- The paper states that additional phase 3 clinical trials are crucial to further evaluate safety and long-term effects.
- The paper states that cost may limit access to retatrutide.
- The paper states that studies assessing the quality of weight loss beyond BMI reduction are lacking.
- Evident from the text: this is a review, not an original study, so its conclusions depend on the included studies rather than new primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
18 Valid · 1 Not valid · 32 Not checked · 8 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, retatrutide showed the largest decreases in food intake, and chronic treatment for 10 days attenuated the described effects.”
§ Retatrutide—A Game Changer in Obesity Pharmacotherapy > 5. Insights from Animal Studies
What the sources say
- Supportedcites [40] Urva, 2023, The Novel GIP, GLP-1 and Glucagon Receptor Agonist Retatrutide Delays Gastric Emptying, Diabetes Obes. Metab. source
Section 3.1 reports that retatrutide produced the largest decreases in food intake in mice and that its effect on gastric emptying was attenuated after 10 days of chronic treatment. The attenuation refers specifically to gastric emptying. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The dual combination of them did not manage to differ statistically from the usage of retatrutide alone.”
§ Retatrutide—A Game Changer in Obesity Pharmacotherapy > 5. Insights from Animal Studies
What the sources say
- Partly supportedcites [40] Urva, 2023, The Novel GIP, GLP-1 and Glucagon Receptor Agonist Retatrutide Delays Gastric Emptying, Diabetes Obes. Metab. sourceExperimental — accuracy not yet measured
Section 3.1 reports that an acute combination treatment did not differ statistically from retatrutide in its effect on gastric emptying in mice. But the combination was semaglutide plus a long-acting glucagon receptor agonist, not semaglutide plus retatrutide. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“10 nmol/kg of retatrutide achieved a bigger weight drop over 10 days than the other combinations.”
§ Retatrutide—A Game Changer in Obesity Pharmacotherapy > 5. Insights from Animal Studies
What the sources say
- Supportedcites [40] Urva, 2023, The Novel GIP, GLP-1 and Glucagon Receptor Agonist Retatrutide Delays Gastric Emptying, Diabetes Obes. Metab. source
Section 2.1 identifies the study animals as obese mice. Section 3.1 reports that 10 nmol/kg retatrutide produced greater body-weight reductions over 10 days than semaglutide, a long-acting glucagon receptor agonist, or their combination. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Retatrutide’s engineering allows it to bind uniquely to these receptors [34].”
§ Retatrutide—A Game Changer in Obesity Pharmacotherapy > 4. General Aspects of Retatrutide > Molecular Structure—Pharmacology
What the sources say
- Supportedcites [34] Li, 2024, Structural Insights into the Triple Agonism at GLP-1R, GIPR and GCGR Manifested by Retatrutide, Cell Discov. source
The structural analysis describes how retatrutide accommodates receptor-specific features while engaging GLP-1R, GIPR and GCGR. The conclusion links its peptide design and distinct receptor interactions to simultaneous agonism at all three receptors. The supplied passages do not give page numbers. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, retatrutide showed the largest decreases in food intake, and chronic treatment for 10 days attenuated the described effects.”
§ Retatrutide—A Game Changer in Obesity Pharmacotherapy > 5. Insights from Animal Studies
What the sources say
- Supportedcites [40] Urva, 2023, The Novel GIP, GLP-1 and Glucagon Receptor Agonist Retatrutide Delays Gastric Emptying, Diabetes Obes. Metab. source
Section 2.1 identifies the experimental animals as obese mice. Section 3.1 states that retatrutide produced the largest decreases in food intake compared with the other treatments; it also reports that its effect on gastric emptying was attenuated after 10 days of chronic treatment. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
23 more claims · 7 with their cited sources checked
Create a free account to see all 59 claims and every source verdict.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“current evidence suggests that retatrutide may represent the most advanced stage in the evolution of incretin therapies, offering simultaneous benefits on obesity, glucose metabolism, and metabolic dysfunctionassociated steatotic liver disease”
From RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW (2026) · cites this paper as KATSI et al., 2025
The cited source says what the claim attributes to it.
In the citing paper
“Recent reviews corroborate these findings and highlight that retatrutide presents an acceptable safety profile and the potential to become established as one of the main pharmacological strategies for the treatment of obesity and its metabolic complications”
From RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW (2026) · cites this paper as KATSI et al., 2025
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952 · cited 1×
“It is estimated to be responsible for approximately 3.4 million deaths each year worldwide, underscoring its severity as a major contributor to mortality rates [1].”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“The emergence of GLP-1 receptor agonists, such as the first clinically approved agonist, exenatide, in 2005, paved the way for the thorough exploration of these molecules [12].”
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Global burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319 · cited 1×
“Added to that, it is constantly growing in scale with an estimated projection of overweight and obese adults at 1.35 billion and 573 million, respectively, by the year 2030 [4].”
InfluentialThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“They are 463 amino acid heptahelical G protein-coupled receptors that, when activated, stimulate cyclic adenosine monophosphate (cAMP) formation followed by activation of protein kinase A pathways [20].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479 · cited 1×
“This has a significant toll on life expectancy, which is shown to be reduced by 7 years at the age of 40 years [3].”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 2×
“In a phase II double-blind, randomized, placebo-controlled trial, Jastreboff et al. administered retatrutide in doses up to 8 mg for a total of 48 weeks in patients with a BMI ≥ 30 kg/m 2 or with a BMI of 27–30 kg/m 2 and a coexisting weight-related condition [39].”
US Preventive Services Task Force, Grossman, D. C., Bibbins-Domingo, K., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.6803 · Cited by 815
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778 · cited 1×
“Notably, adherence to the Mediterranean diet—a dietary pattern rich in fruits, vegetables, whole grains, olive oil, and lean proteins—has demonstrated significant improvements in hepatic steatosis and insulin resistance among patients with MAFLD [10].”
Cited by
Ganamurali, N., & Sabarathinam, S. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70001 · Cited by 8
“38 • Public and policy momentum : Semaglutide and tirzepatide’s extraordinary public adoption has already brought obesity therapy into the mainstream of policy discussions.”
Liu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 10
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“However, a clinical trial (NCT06075667) is underway studying once weekly retatrutide in adolescents aged 12 to 17 years who are obese or overweight with weight-related comorbidities [399].”
Rega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“Retatrutide has demonstrated a safety profile in early clinical testing characterised primarily by transient gastrointestinal toxicity similar to other incretin-based therapies [227,228] (Table 3).”
AL-shibil, Z. M. R., & Kadhim, Z. J. (2026) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2026.1.26 · Cited by 1
“21 Although GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and GIP/GLP-1 dual agonists (e.g., tirze-patide) reliably reduce body weight and improve metabolic outcomes in both humans and rodents, including better glucose control and improved lipid profiles.”
Metadata
- Authors
- Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Katsi, Vasiliki
- ORCID
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2025-05-30
- Volume
- 15
- Issue
- 6
- Pages
- 796
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC12190491
- OpenAlex
- W4410951277
- Cited by
- 29
- References
- 50
- Citations by year
- 2026: 27 · 2025: 2
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- retatrutide, obesity pharmacotherapy, type 2 diabetes, GLP-1 receptor, GIP receptor, glucagon receptor, weight loss, glycemic control, HbA1c, non-alcoholic fatty liver disease, diabetic nephropathy, incretin-based therapy, gastrointestinal adverse effects
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Fatty Acids, Gastric Inhibitory Polypeptide, Humans, Obesity, Peptides, Weight Loss, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retatrutide—A Game Changer in Obesity Pharmacotherapy. https://app.cochat.ai/papers/10.3390/biom15060796
- The paper
- Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025). Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules. https://doi.org/10.3390/biom15060796
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

